Matthias Löhr & Patrick Michl: RNA vaccine | PANCAID Stakeholder Event Snippet #cancerresearch

Concentrating efforts will be crucial to fight pancreatic cancer. Another groundbreaking step in the right direction was the BioNtec mRNA vaccine. But it won't necessarily be the big promises in research that trigger most change, but the gradual steps which eventually make a difference.

Snippet from our recent PANCAID Stakeholder Dialogue Event. Watch the full 2 hours here: https://youtu.be/0CyTCnSFC_c

Read more on the mRNA-based individualized immunotherapy candidate from BioNtech here. https://investors.biontech.de/news-releases/news-release-details/three-year-phase-1-follow-data-mrna-based-individualized/
PANCAID is an international research consortium aiming to develop a minimally invasive blood test using liquid biopsy to detect pancreatic cancer to facilitate early detection of the cancer and its precursors. With 20 members from eight countries, the project has received funding for five years to potentially revolutionize current pancreatic cancer diagnosis methods and improve patient outcomes.
The project has received funding for a duration of five years and started in January 2023.
🌐 More info: https://www.pancaid-project.eu

🤳 Follow us on social media:
LinkedIn: https://www.linkedin.com/company/pancaid/
Bluesky: https://bsky.app/profile/pancaid.bsky.social
Instagram: https://www.instagram.com/pancaid_eu/
🇪🇺 Funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or European Health and Digital Executive Agency (HADEA). Neither the European Union nor the granting authority can be held responsible for them.
Production: concentris
https://www.concentris.de/en/eu-project-management-services/

(c) PANCAID 2026

Видео Matthias Löhr & Patrick Michl: RNA vaccine | PANCAID Stakeholder Event Snippet #cancerresearch канала PANCAID